Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study

IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY International Journal of Impotence Research Pub Date : 2025-01-29 DOI:10.1038/s41443-025-01019-4
Luca Boeri, Giorgio Graps, Ester Zino, Agnese Zago, Andrea Li Puma, Fabio Ciamarra, Antonio Cimmino, Valentina Parolin, Michela Piccoli, Franco Gadda, Emanuele Montanari, Giancarlo Albo
{"title":"Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study","authors":"Luca Boeri, Giorgio Graps, Ester Zino, Agnese Zago, Andrea Li Puma, Fabio Ciamarra, Antonio Cimmino, Valentina Parolin, Michela Piccoli, Franco Gadda, Emanuele Montanari, Giancarlo Albo","doi":"10.1038/s41443-025-01019-4","DOIUrl":null,"url":null,"abstract":"Sildenafil is one of the most used phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction (ED) in clinical practice. A new oral suspension formulation (OSF) of sildenafil has been introduced to overcome the drawbacks of previous formulations. We assess the efficacy and patients’ experience with sildenafil 50 mg OSF in men with ED who were taking the sildenafil oro-dispersible film (ODF). Demographics and clinical data from 70 consecutive men with mild-moderate ED were analysed. Patients were treated with sildenafil 50 mg ODF for 12 weeks (follow-up 1), then, after 2-week washout, were administered sildenafil 50 mg OSF for 12 weeks (follow-up 2). At each follow-up, patients completed the International Index of Erectile Function (IIEF), the Patient Global Impression of Improvement (PGI-I), and the Psychological and Interpersonal Relationship Scales-Short Form (PAIRS-SF) questionnaires. Descriptive statistics described the whole cohort. The Wilcoxon Signed Rank Test assessed potential differences in psychometric scores at different follow-up assessments. Logistic regression analyses tested the associations between study variables and satisfaction after sildenafil OSF treatment. Overall, median age was 56 (51–62) years, and median IIEF-EF score was 14 (12–17). Compared to baseline, IIEF-EF scores significantly improved after sildenafil ODF and OSF treatment (all p < 0.01) with no differences between the two formulations. IIEF-overall satisfaction (OS) was higher after sildenafil OSF than ODF (p < 0.001). Similarly, median PGI-I score were better after sildenafil OSF than ODF (p < 0.001). The PAIRS-SF spontaneity scores were significantly higher after OSF than ODF (p < 0.01). At multivariable logistic regression analysis, younger age (p = 0.02) and lower baseline IIEF-EF scores (p = 0.01) were independent predictors of improved satisfaction with OSF compared to ODF. The sildenafil OSF and ODF had similar efficacy, however the new OSF provides higher satisfaction and spontaneity scores compared to the oro-dispersible film.","PeriodicalId":14068,"journal":{"name":"International Journal of Impotence Research","volume":"37 11","pages":"902-907"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41443-025-01019-4.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Impotence Research","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41443-025-01019-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Sildenafil is one of the most used phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction (ED) in clinical practice. A new oral suspension formulation (OSF) of sildenafil has been introduced to overcome the drawbacks of previous formulations. We assess the efficacy and patients’ experience with sildenafil 50 mg OSF in men with ED who were taking the sildenafil oro-dispersible film (ODF). Demographics and clinical data from 70 consecutive men with mild-moderate ED were analysed. Patients were treated with sildenafil 50 mg ODF for 12 weeks (follow-up 1), then, after 2-week washout, were administered sildenafil 50 mg OSF for 12 weeks (follow-up 2). At each follow-up, patients completed the International Index of Erectile Function (IIEF), the Patient Global Impression of Improvement (PGI-I), and the Psychological and Interpersonal Relationship Scales-Short Form (PAIRS-SF) questionnaires. Descriptive statistics described the whole cohort. The Wilcoxon Signed Rank Test assessed potential differences in psychometric scores at different follow-up assessments. Logistic regression analyses tested the associations between study variables and satisfaction after sildenafil OSF treatment. Overall, median age was 56 (51–62) years, and median IIEF-EF score was 14 (12–17). Compared to baseline, IIEF-EF scores significantly improved after sildenafil ODF and OSF treatment (all p < 0.01) with no differences between the two formulations. IIEF-overall satisfaction (OS) was higher after sildenafil OSF than ODF (p < 0.001). Similarly, median PGI-I score were better after sildenafil OSF than ODF (p < 0.001). The PAIRS-SF spontaneity scores were significantly higher after OSF than ODF (p < 0.01). At multivariable logistic regression analysis, younger age (p = 0.02) and lower baseline IIEF-EF scores (p = 0.01) were independent predictors of improved satisfaction with OSF compared to ODF. The sildenafil OSF and ODF had similar efficacy, however the new OSF provides higher satisfaction and spontaneity scores compared to the oro-dispersible film.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与西地那非或分散膜相比,新型西地那非口服混悬剂的有效性和患者满意度:一项现实生活研究。
西地那非是临床上治疗勃起功能障碍(ED)最常用的磷酸二酯酶5型抑制剂(PDE5i)之一。一种新的口服悬浮液制剂(OSF)的西地那非已被介绍,以克服以往的配方的缺点。我们评估了西地那非50mg OSF对服用西地那非或可分散膜(ODF)的ED男性患者的疗效和患者体验。我们分析了连续70例轻中度ED患者的人口学和临床资料。患者接受西地那非50mg ODF治疗12周(随访1),然后,在2周洗脱期后,给予西地那非50mg OSF治疗12周(随访2)。在每次随访中,患者完成国际勃起功能指数(IIEF),患者整体改善印象(PGI-I)和心理和人际关系量表-短表格(PAIRS-SF)问卷。描述性统计描述了整个队列。Wilcoxon sign Rank检验评估了不同随访评估中心理测量分数的潜在差异。Logistic回归分析检验了研究变量与西地那非OSF治疗后满意度之间的关系。总体而言,中位年龄为56(51-62)岁,中位IIEF-EF评分为14(12-17)。与基线相比,西地那非ODF和OSF治疗后IIEF-EF评分显著提高(p < 0.05)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Impotence Research
International Journal of Impotence Research 医学-泌尿学与肾脏学
CiteScore
4.90
自引率
19.20%
发文量
140
审稿时长
>12 weeks
期刊介绍: International Journal of Impotence Research: The Journal of Sexual Medicine addresses sexual medicine for both genders as an interdisciplinary field. This includes basic science researchers, urologists, endocrinologists, cardiologists, family practitioners, gynecologists, internists, neurologists, psychiatrists, psychologists, radiologists and other health care clinicians.
期刊最新文献
Comment on: Zero infection protocol in inflatable penile prosthesis surgery: a prospective cohort study using chlorhexidine-alcohol skin preparation and fibrin sealant hemostasis. Response to comment on: zero infection protocol in inflatable penile prosthesis Surgery: a prospective cohort study using chlorhexidine-alcohol skin preparation and fibrin sealant hemostasis. The Orgasmometer-m: validation in Mandarin and measurement of orgasmic intensity in the Han population affected by premature ejaculation. The role of sleep stages in the regulation of erectile function: impacts of REM sleep fragmentation. Maternal sexuality in high- and low-risk pregnancies: a cross-sectional comparison.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1